Rapharma received registration certificate ЛП-№(000744)-(РГ-RU) for its drug Oliramus drug (INN Everolimus) from the Ministry of Health of the Russian Federation. The drug will be available to patients in three dosages (2.5 mg, 5 mg, and 10 mg). This is reported on the company’s official website.
Oliramus antitumor therapy is a protein kinase inhibitor (mammalian target of rapamycin (mTOR) inhibitor) for oral administration. The drug is indicated for adult patients with the following conditions:
- Advanced and/or metastatic renal cell carcinoma with ineffective anti-angiogenic therapy.
- Gastrointestinal and pulmonary advanced and/or metastatic neuroendocrine tumors.
- Hormone-dependent advanced breast cancer in postmenopausal patients in combination with an aromatase inhibitor, after endocrine therapy.
“Oliramus acts by suppressing protein kinase, thereby reducing blood supply to the tumor and slowing down the growth and spread of cancer cells. The efficacy, tolerability and safety of Everolimus has been confirmed in a large number of clinical trials,” the report says.
AO Rapharma, together with ZAO PharmFirma Sotex, forms the basis of the production segment of Protek group, the company stressed.